about
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Dapagliflozin for the treatment of type 1 diabetes mellitus.Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Tofogliflozin: the road goes ever on.
@en
Tofogliflozin: the road goes ever on.
@nl
type
label
Tofogliflozin: the road goes ever on.
@en
Tofogliflozin: the road goes ever on.
@nl
prefLabel
Tofogliflozin: the road goes ever on.
@en
Tofogliflozin: the road goes ever on.
@nl
P2860
P1476
Tofogliflozin: the road goes ever on.
@en
P2093
Kalliopi Pafili
Nikolaos Papanas
P2860
P304
P356
10.1517/14656566.2014.916278
P407
P577
2014-04-30T00:00:00Z